erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
.
.
the youngest claimant was aged 20, and the eldest aged 89, while the average policy duration at claim stage was 10 years..
.
it's the first successful medical treatment of a human fetus for the underlying cause of a genetic disorder, experts say.
media won�t investigate medically-caused death numbers.